Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 6 studies | 35% ± 14% | |
epithelial cell of proximal tubule | 5 studies | 23% ± 6% | |
kidney loop of Henle epithelial cell | 4 studies | 18% ± 1% | |
cardiac muscle cell | 4 studies | 18% ± 1% | |
goblet cell | 4 studies | 18% ± 3% | |
ciliated cell | 3 studies | 23% ± 3% | |
GABAergic neuron | 3 studies | 34% ± 7% | |
glutamatergic neuron | 3 studies | 30% ± 13% | |
intestinal crypt stem cell | 3 studies | 21% ± 5% | |
basal cell | 3 studies | 32% ± 6% | |
transit amplifying cell | 3 studies | 32% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1218.03 | 245 / 245 | 99% | 58.85 | 498 / 502 |
thymus | 100% | 2064.61 | 653 / 653 | 99% | 59.47 | 600 / 605 |
uterus | 100% | 989.62 | 170 / 170 | 98% | 40.54 | 450 / 459 |
intestine | 99% | 1042.44 | 961 / 966 | 97% | 61.38 | 513 / 527 |
ovary | 100% | 1212.61 | 180 / 180 | 97% | 39.56 | 416 / 430 |
stomach | 100% | 1129.14 | 358 / 359 | 97% | 49.85 | 276 / 286 |
breast | 100% | 1075.70 | 459 / 459 | 95% | 35.44 | 1067 / 1118 |
pancreas | 100% | 1477.68 | 328 / 328 | 95% | 26.18 | 169 / 178 |
bladder | 100% | 1005.71 | 21 / 21 | 95% | 45.00 | 477 / 504 |
brain | 96% | 646.86 | 2527 / 2642 | 99% | 36.08 | 697 / 705 |
esophagus | 100% | 1019.17 | 1441 / 1445 | 95% | 29.04 | 173 / 183 |
kidney | 100% | 2513.45 | 89 / 89 | 94% | 32.74 | 846 / 901 |
adrenal gland | 98% | 772.59 | 253 / 258 | 96% | 36.73 | 220 / 230 |
lung | 98% | 648.66 | 566 / 578 | 93% | 25.98 | 1079 / 1155 |
skin | 99% | 1140.16 | 1787 / 1809 | 91% | 34.89 | 430 / 472 |
liver | 99% | 1374.09 | 224 / 226 | 91% | 31.30 | 368 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 120.64 | 80 / 80 |
muscle | 100% | 8154.79 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.88 | 1 / 1 |
heart | 100% | 2531.99 | 857 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 799.69 | 1323 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 752.95 | 1193 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 29.34 | 43 / 45 |
spleen | 91% | 393.06 | 219 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 34% | 8.21 | 10 / 29 |
peripheral blood | 19% | 99.15 | 181 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042278 | Biological process | purine nucleoside metabolic process |
GO_0006974 | Biological process | DNA damage response |
GO_0051725 | Biological process | protein de-ADP-ribosylation |
GO_0140291 | Biological process | peptidyl-glutamate ADP-deribosylation |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0140293 | Molecular function | ADP-ribosylglutamate hydrolase activity |
GO_0019213 | Molecular function | deacetylase activity |
GO_0016798 | Molecular function | hydrolase activity, acting on glycosyl bonds |
GO_0005515 | Molecular function | protein binding |
Gene name | MACROD1 |
Protein name | ADP-ribose glycohydrolase MACROD1 (MACRO domain-containing protein 1) (O-acetyl-ADP-ribose deacetylase MACROD1) (EC 3.1.1.106) (Protein LRP16) ([Protein ADP-ribosylaspartate] hydrolase MACROD1) (EC 3.2.2.-) ([Protein ADP-ribosylglutamate] hydrolase MACROD1) (EC 3.2.2.-) Mono-ADP ribosylhydrolase 1 |
Synonyms | LRP16 |
Description | FUNCTION: Removes ADP-ribose from aspartate and glutamate residues in proteins bearing a single ADP-ribose moiety . Inactive towards proteins bearing poly-ADP-ribose . Deacetylates O-acetyl-ADP ribose, a signaling molecule generated by the deacetylation of acetylated lysine residues in histones and other proteins . Plays a role in estrogen signaling . Binds to androgen receptor (AR) and amplifies the transactivation function of AR in response to androgen . May play an important role in carcinogenesis and/or progression of hormone-dependent cancers by feed-forward mechanism that activates ESR1 transactivation . Could be an ESR1 coactivator, providing a positive feedback regulatory loop for ESR1 signal transduction . Could be involved in invasive growth by down-regulating CDH1 in endometrial cancer cells . Enhances ESR1-mediated transcription activity . . |
Accessions | Q9BQ69 A0A6Q8PH91 ENST00000675777.1 ENST00000255681.7 |